23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Olema Pharmaceuticals, Inc. › 2025-2026

Olema Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Olema Pharmaceuticals, Inc.’s Form 8-K, filed June 23, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 217Asset managers, any item
  • 1,526Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 6 items on Olema Pharmaceuticals, Inc.’s Form 8-K, filed June 23, 2026: 4 elected · 2 approved.

Dissent

Significant dissent: 1 director (26.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Olema Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Olema Pharmaceuticals, Inc.

These tallies are Olema Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Olema Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sean Bohen, M.D., Ph.D. 67,474,365---- 1,165,3827,496,139 98%Elected—
Elect Director: Scott Garland 66,184,382---- 2,455,3657,496,139 96%Elected—
Elect Director: Yi Larson 50,371,668---- 18,268,0797,496,139 73%Elected—
Elect Director: Andrew Rappaport 67,276,575---- 1,363,1727,496,139 98%Elected—
2. Advisory Vote on Executive Compensation Final Voting Results 67,969,902653,97915,867 --7,496,139 99.0%Approved—
3. Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results 75,811,449271,91852,520 ---- 99.6%Approved—

Source: Olema Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 23, 2026 — read the filing on EDGAR.

How asset managers voted at the Olema Pharmaceuticals, Inc. 2025-2026 meeting

217 asset managers disclosed a vote on at least one Olema Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Sean Bohen, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 67,474,365WITHHELD: 1,165,382
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sean Bohen, M.D., Ph.D.

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Sean Bohen, M.D., Ph.D.”): 67,474,365 for, 1,165,382 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,395,814 for, 380,132 withheld, 17,295 abstained.

FOR
FOR: 24,395,814ABSTAIN: 17,295WITHHOLD: 380,132
Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,687,4630 34,790For
State Street2,728,7200 03,600For
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM685,5450 04,084For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital444,0830 00For
Dimensional00 0351,809Withhold
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable103,3040 00For
Voya99,1990 00For
Tema ETF Trust80,7910 00For
Lincoln Financial71,4510 05,674Mixed
American Century74,8630 00For
ALPS ETF Trust71,8980 00For
ProShares70,6740 00For
JPMorgan65,9640 00For
Delaware/Macquarie50,0000 00For
AIG/SunAmerica49,1560 00For
Goldman Sachs41,3030 00For
MFS39,0180 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Scott Garland

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 66,184,382WITHHELD: 2,455,365
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Scott Garland

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Garland”): 66,184,382 for, 2,455,365 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,131,081 for, 644,861 withheld, 17,299 abstained.

FOR
FOR: 24,131,081ABSTAIN: 17,299WITHHOLD: 644,861
Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,692,2490 70For
State Street2,732,3200 00For
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM685,5450 04,084For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital444,0830 00For
Dimensional00 0351,809Withhold
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable65,9240 037,380Mixed
Voya00 099,199Withhold
Tema ETF Trust80,7910 00For
Lincoln Financial71,4510 05,674Mixed
American Century74,8630 00For
ALPS ETF Trust71,8980 00For
ProShares70,6740 00For
JPMorgan65,9640 00For
Delaware/Macquarie00 050,000Withhold
AIG/SunAmerica49,1560 00For
Goldman Sachs37,1840 04,119Mixed
MFS00 039,018Withhold

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Yi Larson

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD
FOR: 50,371,668WITHHELD: 18,268,079
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Yi Larson

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yi Larson”): 50,371,668 for, 18,268,079 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 20,488,431 for, 4,245,528 withheld, 59,282 abstained.

FORWITHHOLD
FOR: 20,488,431ABSTAIN: 59,282WITHHOLD: 4,245,528
Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,685,0890 217,146For
State Street2,0030 02,730,317Withhold
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM685,5450 04,084For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital00 0444,083Withhold
Dimensional00 0351,809Withhold
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable65,9240 037,380Mixed
Voya00 099,199Withhold
Tema ETF Trust80,7910 00For
Lincoln Financial00 077,125Withhold
American Century00 074,863Withhold
ALPS ETF Trust00 071,898Withhold
ProShares00 070,674Withhold
JPMorgan65,9640 00For
Delaware/Macquarie00 050,000Withhold
AIG/SunAmerica00 049,156Withhold
Goldman Sachs41,3030 00For
MFS00 039,018Withhold

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Andrew Rappaport

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 67,276,575WITHHELD: 1,363,172
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Andrew Rappaport

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Rappaport”): 67,276,575 for, 1,363,172 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,358,353 for, 417,593 withheld, 17,295 abstained.

FOR
FOR: 24,358,353ABSTAIN: 17,295WITHHOLD: 417,593
Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,687,4630 34,790For
State Street2,728,6390 03,681For
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM685,5450 04,084For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital444,0830 00For
Dimensional00 0351,809Withhold
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable65,9240 037,380Mixed
Voya99,1990 00For
Tema ETF Trust80,7910 00For
Lincoln Financial71,4510 05,674Mixed
American Century74,8630 00For
ALPS ETF Trust71,8980 00For
ProShares70,6740 00For
JPMorgan65,9640 00For
Delaware/Macquarie50,0000 00For
AIG/SunAmerica49,1560 00For
Goldman Sachs41,3030 00For
MFS39,0180 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Advisory Vote on Executive Compensation Final Voting Results

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.0% Approved · of votes cast

FOR 99.0%
FOR: 67,969,902AGAINST: 653,979

Prior year: 95.9% for (June 10, 2025 meeting) ▲ 3.1 pts

Details: description as filed, official tally, votes by 213 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers.

Olema Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory Vote on Executive Compensation Final Voting Results”): 67,969,902 for, 653,979 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Olema Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “14A Executive Compensation” (4 managers, 2,666,277 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 61 asset managers voting on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,692,2533 00For
State Street2,731,1831,137 00For
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM689,6290 00For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital444,0830 00For
Dimensional351,8090 00For
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable103,3040 00For
Voya99,1990 00For
Tema ETF Trust80,7910 00For
Lincoln Financial77,1250 00For
American Century074,863 00Against
ALPS ETF Trust71,8980 00For
ProShares70,6740 00For
JPMorgan65,9640 00For
Putnam59,6050 00For
Delaware/Macquarie50,0000 00For
AIG/SunAmerica49,1560 00For
Franklin Alternative Strategies Funds42,3190 00For

Fund voting reports, all 61 managers: 24,793,254 for, 84,625 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 171 asset managers voting on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,002,1340 00For
Janus Henderson8,083,2460 00For
Paradigm Biocapital Advisors LP7,387,7050 00For
BVF INC/IL5,295,8930 00For
Siren, L.L.C.4,856,9490 00For
State Street3,987,05310,012 00For
Polar Capital Holdings Plc3,205,9400 00For
BlackRock1,679,66625,976 00For
GEODE CAPITAL MANAGEMENT, LLC1,578,5730 00For
FRANKLIN ADVISERS INC1,448,2070 00For
Logos Global Management LP1,371,1270 00For
Cormorant Asset Management, LP1,350,0940 00For
JENNISON ASSOCIATES LLC1,058,7390 00For
Duquesne Family Office LLC986,8270 00For
KINGDON CAPITAL MANAGEMENT, L.L.C.855,0000 00For
T. Rowe Price816,0450 00For
Candriam S.C.A.0737,513 00Against
Vivo Capital, LLC671,8430 00For
Charles Schwab466,5100 00For
Victory Capital460,2730 00For
Vanguard441,5620 00For
Northern Trust401,3046,024 00For
Wellington367,0610 00For
Woodline Partners LP300,1530 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.250,0120 00For

Institutional-manager reports, all 171 managers: 60,990,690 for, 1,036,077 against, 12 abstained, 94 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 75,811,449AGAINST: 271,918

Prior year: 100.0% for (June 10, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

Olema Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 75,811,449 for, 271,918 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 24,877,879 for.

FOR
FOR: 24,877,879
Largest asset managers voting on “Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Com” at Olema Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity10,291,3140 00For
Vanguard3,692,2560 00For
State Street2,732,3200 00For
BlackRock2,237,0830 00For
JANUS INVESTMENT FUND960,5800 00For
FRANKLIN STRATEGIC SERIES761,9410 00For
Prudential/PGIM689,6290 00For
T. Rowe Price634,3700 00For
Charles Schwab466,4470 00For
Victory Capital444,0830 00For
Dimensional351,8090 00For
TIAA132,6180 00For
QUANTITATIVE MASTER SERIES LLC113,5040 00For
Equitable103,3040 00For
Voya99,1990 00For
Tema ETF Trust80,7910 00For
Lincoln Financial77,1250 00For
American Century74,8630 00For
ALPS ETF Trust71,8980 00For
ProShares70,6740 00For
JPMorgan65,9640 00For
Putnam59,6050 00For
Delaware/Macquarie50,0000 00For
AIG/SunAmerica49,1560 00For
Franklin Alternative Strategies Funds42,3190 00For

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Largest Olema Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,332,971 shares outstanding at the time of that meeting.

Fund voting reports: top Olema Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.78%
2Vanguard 4.23%
3State Street 3.13%
4BlackRock 2.56%
5JANUS INVESTMENT FUND 1.10%
6FRANKLIN STRATEGIC SERIES 0.87%
7Prudential/PGIM 0.79%
8T. Rowe Price 0.73%
9Charles Schwab 0.53%
10Victory Capital 0.51%
Institutional-manager reports: top Olema Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.45%
2Janus Henderson 9.26%
3Paradigm Biocapital Advisors LP 8.46%
4BVF INC/IL 6.06%
5Siren, L.L.C. 5.56%
6State Street 4.58%
7Polar Capital Holdings Plc 3.67%
8BlackRock 1.95%
9GEODE CAPITAL MANAGEMENT, LLC 1.81%
10FRANKLIN ADVISERS INC 1.66%

Reported Olema Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Olema Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)10,386,845 11.89%Form 13F, quarter ended March 31, 2026
JANUS HENDERSON GROUP PLC7,108,488 8.14%Schedule 13G, filed May 15, 2026
BlackRock5,652,135 6.47%Form 13F, quarter ended March 31, 2026
Raymond Debbane4,461,949 5.11%Schedule 13G, filed March 20, 2026
State Street3,937,831 4.51%Form 13F, quarter ended March 31, 2026
Vanguard Group3,561,355 4.08%Form 13F, quarter ended March 31, 2026
Geode Capital1,544,417 1.77%Form 13F, quarter ended March 31, 2026
Goldman Sachs1,252,689 1.43%Form 13F, quarter ended March 31, 2026
Franklin Templeton1,218,957 1.40%Form 13F, quarter ended March 31, 2026
T. Rowe Price1,182,836 1.35%Form 13F, quarter ended March 31, 2026

Percentages above are of 87,332,971 shares outstanding, as reported by Olema Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Olema Pharmaceuticals, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 217 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,526 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the Company's named executive officers. — Olema Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 99.0% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Olema Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Olema Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Olema Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Olema Pharmaceuticals (OLMA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/olema-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.